Cerenome (CNSY) vs Femasys (FEMY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Femasys (FEMY) has outperformed Cerenome (CNSY) over the past year, losing 84.6% versus a loss of 89.3%. Over five years, FEMY leads with a -98.5% price change compared with -99.7% for CNSY. Femasys is the larger company by market cap ($16.8 million vs $14.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNSY | FEMY |
|---|---|---|
| Share price | $1.93 | $2.00 |
| Market cap | $14.65M | $16.75M |
| 1-day change | +7.82% | -2.20% |
| YTD return | -84.86% | -82.64% |
| 1-year return | -89.28% | -84.59% |
| 5-year return | -99.71% | -98.54% |
| EPS (TTM) | $-3.36 | $-3.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.00 | $22.20 |
| 52-week low | $1.49 | $1.94 |
| Distance from 52-week high | -89.84% | -90.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1337.82% | +616.50% |
| Average volume | 121.94K | 733.12K |
| Shares outstanding | 7.59M | 8.38M |
| Employees | 28 | 51 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cerenome
CNSY stock →Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
Health Care · Medical/Dental Instruments · 28 employees
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Health Care · Medical/Dental Instruments · 51 employees
CNSY vs FEMY FAQ
Which is bigger, Cerenome or Femasys?
Femasys (FEMY) is larger, with a market capitalization of $16.75M compared with $14.65M for Cerenome (CNSY).
Which stock has performed better over the past year, CNSY or FEMY?
FEMY returned -84.59% over the past 12 months, compared with -89.28% for CNSY (price return, excluding dividends). Past performance does not predict future results.
Are Cerenome and Femasys in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.